Article: A Bull Market in Stock Bashing and 12 Stories from New Cannabis Ventures

Article - Media, Publications

A Bull Market in Stock Bashing and 12 Stories from New Cannabis Ventures

Alan Brochstein, 06 May 2018

With so much interest in the the cannabis sector, we have noticed an increase in the number of bearish pieces on publicly-traded companies on platforms like Seeking Alpha. This week, for instance, an article called for an 80% decline in Namaste Technologies. The same writer, “Grumpy Bear Research”, took a shot at Isodiol International in the prior week. Many of the leading LPs in Canada have been the subject of these attacks as well, including, most recently, Aphria.

We aren’t going to weigh in on the validity of the arguments made or our views of these companies, but we do want to discuss the bigger picture. Many, though certainly not all, of these articles are very well researched and bring out information that is new to many investors in the company, often a reflection of the lack of due diligence done by retail investors and the void in negative research published by the Canadian investment banking firms that cover the space.
Continue reading “Article: A Bull Market in Stock Bashing and 12 Stories from New Cannabis Ventures”

Article: Isodiol International Inc. (ISOLF): $ISOLF news out!

Article - Media, Publications

Isodiol International Inc. (ISOLF): $ISOLF news out!”

stockman69, 25 April 2018

It has come to the attention of Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”) that an anonymous author by the fictitious name “Grumpy Bear” has posted a lengthy article on the website that is intended to disparage the Company by any means possible. While Isodiol has a general policy of not responding to anonymous media and online postings, this particular article is the first of its kind, has had wide dissemination, and has a misleading air of credibility due to the website where it was posted.

We wish to be clear. The author is not credible, and the article is not credible. The author has written four articles under the Grumpy Bear alias, and each one appears timed to an artificial sell-off in the stock of the target issuer for the benefit of a specific short-selling fund group. There also is evidence that suggests the real people behind the Grumpy Bear alias have engaged in similar tactics for the better part of the last decade under other aliases, two of which have resulted in several hundred million dollar lawsuits against the fund group.
Moreover, the article was not written to journalistic or regulated research analyst standards and has no such integrity. Other than scattered facts with citations to voluntary public disclosures by the Company and certain other limited public information, the article is fiction. The fictional and defamatory nature of the article also is why the true identity of Grumpy Bear is concealed by use of an anonymous third-party e-mail server based in Switzerland. Isodiol intends to pursue all available legal remedies against the author and these artificial short sellers.
Continue reading “Article: Isodiol International Inc. (ISOLF): $ISOLF news out!”

Article: Isodiol Is MJNA 2.0 – Expect Massive Dilution From Not-So-Arm’s-Length Transactions

Article - Media, Publications

Isodiol Is MJNA 2.0 – Expect Massive Dilution From Not-So-Arm’s-Length Transactions

Grumpy Bear Research, 23 April 2018

During the past few months, Isodiol International Inc. (OTCQB:ISOLF) has seen its stock price rocket up by over 300%, giving it a market capitalization of about CAD$300 million (CAD$424 million fully diluted). The company has the appearance of a rapidly growing business in phytoceuticals (plant-based health supplements) that focused on derivatives of hemp. Hemp is a cousin to the cannabis plant and is a source of non-narcotic cannabidiol (“CBD”), which is used in many nutraceutical products and is presumptively legal throughout the United States.

Revenues have also gone up exponentially at Isodiol in the past year, due largely to a plethora of acquisitions. In fact, the company actually delivered sales of CAD$5.9 million for the quarter ended December 31, 2017, which was an enormous increase over the CAD$3 million of revenue just two quarters ago. While they only eked out a small net profit of CAD$0.2 million, with that kind of revenue growth, the obvious sales pitch is that Isodiol is a rapidly growing company in the red-hot marijuana sector…even though they are not selling marijuana. Isodiol CEO, Marcos Agramont indicated his confidence in the company’s future by stating “We had another strong quarter of revenue growth and will continue our commitment to delivering high-quality hemp-derived CBD products through innovative delivery methods, which is the core of our success”.
Continue reading “Article: Isodiol Is MJNA 2.0 – Expect Massive Dilution From Not-So-Arm’s-Length Transactions”